Dark

Check out our API

PSTI
Pluristem Therapeutics, Inc.
stock NASDAQ

Inactive

Jul 25, 2022

1.00USD-2.913%(-0.03)170,627

Pre-market

0.00USD-100.000%(-1.03)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 10, 2022

10:31AM EST Pluristem Climbs On Collaboration With Tnuva Of Israel For RTTNews

05:12AM EST Pluristem, and Israel's Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform; NewCo to Receive Licensing Rights to Use Pluristem Technology; Truva to Invest $7.5M initially in NewCo Benzinga

03:00AM EST Biotechnology Company Pluristem, and Israels GlobeNewswire Inc

Dec 27, 2021

07:41AM EST Pluristem: Phase II Studies Of ARDS Associated With RTTNews

07:28AM EST Pluristem: Phase II Studies Of Acute Respiratory Distress Syndrome With COVID-19 Misses Endpoint RTTNews

07:06AM EST Pluristem Reports Results From Its Phase II Studies Of Acute Respiratory Distress Syndrome Associated With COVID-19 Did Not Meet The Primary Efficacy Endpoint Of Statistically Significant Improvement Of VFD At 28 Days Benzinga

07:00AM EST Pluristem Reports Topline Results from its Phase II Studies of GlobeNewswire Inc

Dec 9, 2021

09:53PM EST From Benzinga's Global Small Cap Conference: Pluristem Therapeutics President & CEO, Yaky Yanay Says Co PLX-PAD Demonstrated A Significant Increase In Muscle Strength Volume Compare To Placebo Benzinga

09:53PM EST From Benzinga's Global Small Cap Conference: Pluristem Therapeutics President & CEO, Yaky Yanay Says Co Has $80 Million Cash On Hand Benzinga

09:52PM EST From Benzinga's Global Small Cap Conference: Pluristem Therapeutics President & CEO, Yaky Yanay Begins Presenting Benzinga

Nov 15, 2021

10:57AM EST Pluristem Completes Enrollment Of Its Multinational Phase III Study Of Muscle Regeneration Following Hip Fracture Surgery Benzinga

07:10AM EST Having recruited patients in the U.S., Europe and Israel, the Company anticipates topline results in the third calendar quarter of2022 GlobeNewswire Inc

Nov 10, 2021

07:24AM EST Pluristem Announced it Received Approval for Grant from the Israel Innovation Authority to Develop its Next-Generation CRISPR PLX Platform Benzinga

07:00AM EST Pluristem Receives Approval for Grant from the Israel Innovation GlobeNewswire Inc

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 29, 2021

08:13AM EDT The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug Benzinga

Sep 28, 2021

08:18AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive Benzinga

08:16AM EDT The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments Benzinga

Sep 22, 2021

08:15AM EDT Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay. GlobeNewswire Inc

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 6, 2021

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

Jul 29, 2021

03:02PM EDT Longeveron's Novel Therapy Looks to Tackle COVID-19, Flu-Related ARDS Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 19, 2021

07:00AM EDT Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to GlobeNewswire Inc

Jul 8, 2021

07:14AM EDT Pluristem Says Is Bringing 'ARDS Associated with COVID-19 Phase II Studies' To Clinical Readout; Topline Results Expected During Q4 Benzinga

07:12AM EDT -- The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and Israel -- Topline results are expected during the fourth quarter of 2021 GlobeNewswire Inc

Jul 2, 2021

12:04AM EDT Cathie Wood Sells $11M In Roku Benzinga

May 25, 2021

08:48AM EDT Pluristem Stock is Trading Higher After 20M Non-Dilutive Funding from European Investment Bank Benzinga

07:12AM EDT Pluristem To Receive 20M Non-Dilutive Funding From The European Investment Bank Benzinga

07:00AM EDT Pluristem to Receive 20M Non-Dilutive Funding GlobeNewswire Inc

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

May 4, 2021

10:09AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2021 Benzinga

09:16AM EDT Cathie Wood Loads Up More On Alibaba Rivals Pinduoduo, JD Also Adds Skillz Benzinga

08:52AM EDT Alliance Global Partners Initiates Coverage On Pluristem Therapeutics with Buy Rating, Announces Price Target of $12.5 Benzinga

12:17AM EDT Cathie Wood Loads Up More On Alibaba Rivals Pinduoduo, JD Also Adds Skillz Benzinga

Apr 30, 2021

10:19AM EDT Cathie Wood Piles Up Teladoc As Shares Slump On Q1 Miss, Also Adds More Tesla Benzinga

Apr 29, 2021

09:42AM EDT Pluristem Stock Is Trading Higher As PLX-R18 Shows Regenerative Potential In Patients After Bone Marrow Transplant Benzinga

07:37AM EDT Pluristem Reports Positive Topline Phase I Results In Innovative Hematology Program, Which Is First To Study PLX-R18 In Humans Benzinga

07:00AM EDT -- New therapy has potential to generate improved blood counts in all three blood cell lineages, a meaningful advantage over existing treatments -- The company will conduct an analyst and investor call on May 3, 2021, at 10am EDT GlobeNewswire Inc

Apr 22, 2021

12:16PM EDT Pluristem US Patent & Trademark Office Abstract For 'ADHERENT STROMAL CELLS DERIVED FROM PLACENTAS OF MULTIPLE DONORS AND USES THEREOF' Benzinga

Apr 20, 2021

08:07AM EDT The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex Benzinga

Mar 30, 2021

12:04AM EDT Apple, Netflix, Peloton, Square, Roku, DraftKings - What Cathie Wood's Ark Bought And Sold On Monday Benzinga

Mar 2, 2021

06:54PM EST ARK Invest's Cathie Wood To Appear On Benzinga's 'The Raz Report' Wednesday, Mar. 3, 2021 At 2 p.m. EST; Register Early For A Chance To Win To Ask Cathie A Question Live On Air Benzinga

Feb 2, 2021

08:42AM EST Pluristem Shares Were Halted Early Tuesday Ahead Of Offering News; Stock To Resume Trade At 9:15 a.m. EST Benzinga

08:34AM EST Pluristem Therapeutics Announces $30M Registered Direct Offering Benzinga

08:30AM EST Pluristem Therapeutics Inc. Announces $30 Million Registered GlobeNewswire Inc

Jan 27, 2021

07:00AM EST Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced that effective as of market open on January 29, 2021, its common shares have been approved for listing to the Nasdaq Global Market and will continue trading under the company's current ticker symbol PSTI. GlobeNewswire Inc

Jan 6, 2021

07:00AM EST Pluristem Announces Appointments of Two Directors to Board GlobeNewswire Inc

Dec 29, 2020

07:23AM EST Pluristem Therapeutics Inc. (PSTI) said Tuesday that it has reached a collaboration agreement with Mexican pharmaceutical company Innovare R&D to expand its ongoing clinical program of PLX cells in the treatment of Acute Respiratory Distress Syndrome or ARDS associated with COVID-19 in Mexico. RTTNews

07:06AM EST Pluristem Enters Collaboration Agreement With Innovare R&D RTTNews

07:01AM EST Pluristem Enters Collaboration With Innovare R&D To Expand Pluristem's ARDS Associated With COVID-19 Program To Mexico Benzinga

07:00AM EST Pluristem Enters Collaboration With Pharmaceutical Company GlobeNewswire Inc

Dec 10, 2020

07:21AM EST Jefferies Downgrades Pluristem Therapeutics to Hold, Announces $6 Price Target Benzinga

06:08AM EST HC Wainwright & Co. Maintains Buy on Pluristem Therapeutics, Lowers Price Target to $9 Benzinga

Dec 9, 2020

02:55PM EST Mid-Afternoon Market Update: Nasdaq Tumbles 2%; DoorDash Shares Spike Higher Benzinga

12:23PM EST Mid-Day Market Update: Dow Drops Over 100 Points; Rocket Pharmaceuticals Shares Jump Benzinga

10:23AM EST Mid-Morning Market Update: Markets Mixed; Campbell Soup Profit Tops Views Benzinga

05:34AM EST Pluristem Announced DMC Concluded that CLI Study is Unlikely to Meet Primary Endpoint Benzinga

04:29AM EST Pluristem Therapeutics Inc. (PSTI) announced that the independent Data Monitoring Committee of its global pivotal Phase III study for the treatment of critical limb ischemia or CLI issued its recommendation letter that the study is unlikely to meet the primary endpoint by the time of final analysis. RTTNews

04:10AM EST Pluristem To Terminate CLI Study After DMC Recommendation; Study Unlikely To Meet Primary Endpoint RTTNews

04:00AM EST Pluristem Announces DMC Recommendation Following Interim Analysis GlobeNewswire Inc

Nov 29, 2020

08:59AM EST The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions Benzinga

Nov 18, 2020

07:06AM EST Pluristem To Present Initial Results From Its Phase I HCT Study With PLX-R18 Demonstrating Safety And Efficacy At ASH Annual Meeting Benzinga

07:00AM EST -- PLX-R18 demonstrated significant clinicalimprovements in Hb, ANC, and PLT among the high-dose cohort -- PLX-R18 was found to be safe and well-tolerated -- Topline results from the full Phase I clinical trialexpected in Q1 2021 (n=21) GlobeNewswire Inc

Oct 20, 2020

07:00AM EDT World Experts in Infectious Diseases & Critical Care Form GlobeNewswire Inc

Oct 13, 2020

07:16AM EDT Pluristem Gets Clearance To Move Forward With Enrollment For Cohort II In Investigator-Led Phase I/II Chronic Graft RTTNews

07:06AM EDT Pluristem Announces Clearance To Move Forward With Enrollment For Cohort II In Investigator-Led Phase I/II Chronic Graft vs Host Disease Study Benzinga

07:00AM EDT Pluristem Announces Clearance to Move Forward with Enrollment for GlobeNewswire Inc

Oct 7, 2020

02:00AM EDT Pluristem Expands its Phase II COVID-19 European Clinical Trial to GlobeNewswire Inc

Oct 1, 2020

05:01PM EDT 4 Sectors Moving Up In Thursday's After-Market Session Benzinga

04:16PM EDT Clover Wolf Capital-Limited Partnership Reports In Form4 Filing Purchases 7.84M Shares Of Pluristem Therapeutics Benzinga

04:14PM EDT PLURISTEM THERAPEUTICS INC: CLOVER WOLF CAPITAL - LIMITED PARTNERSHIP (10%+) Buys 199,129 @ Avg Price: $10.16 (Form4) Benzinga

05:36AM EDT Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects at Malta Conferences Foundation Online Event Benzinga

03:00AM EDT The Malta Conferences address the shared desire to improve quality of life and political stability in the Middle East through scientific collaboration GlobeNewswire Inc

Sep 15, 2020

07:47AM EDT Pluristem Therapeutics Pres, CEO Sends Letter To Shareholders Benzinga

07:30AM EDT Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay. GlobeNewswire Inc

Aug 27, 2020

07:01AM EDT Pluristem Announces FDA Has Cleared Co.'s Expanded Access For Use Of PLX-PAD Cells In Acute Respiratory Distress Syndrome Caused By COVID-19 Benzinga

07:00AM EDT Pluristem Launches FDA-Cleared COVID-19 Expanded Access Program, GlobeNewswire Inc

Aug 19, 2020

07:08AM EDT Pluristem Announces End Of Patient Enrollment In Phase I Hematology Study Benzinga

07:00AM EDT Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today it has completed patient enrollment in its Phase I study evaluating PLX-R18 as a treatment for incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT), in the U.S. and in Israel. GlobeNewswire Inc

Aug 17, 2020

02:43AM EDT Pluristem Signs Non-binding MOU With Abu Dhabi Stem Cells Center RTTNews

02:00AM EDT Pluristem and Abu Dhabi Stem Cells Center Sign MOU to Collaborate GlobeNewswire Inc

Aug 10, 2020

07:02AM EDT Pluristem Expands COVID-19 Program To Europe, Receives PEI Clearance To Commence Phase II Study In Germany Benzinga

07:00AM EDT Pluristem Expands its COVID-19 Program to Europe, Receives PEI GlobeNewswire Inc

Jul 24, 2020

09:29AM EDT Jefferies Maintains Buy on Pluristem Therapeutics, Raises Price Target to $16 Benzinga

Jul 21, 2020

07:14AM EDT Pluristem CEO Issues Shareholder Update On Clinical Programs; Says Had $59M In Cash And Equivalents As Of Jun. 30 Benzinga

07:10AM EDT Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, today issued an update to its shareholders from its Chief Executive Officer and President, Yaky Yanay. GlobeNewswire Inc

Jul 16, 2020

05:31PM EDT Pluristem Therapeutics On July 16 Entered Into Open Market Sale Agreement With Jefferies; May Issue And Sell Common Shares Of Up To $75M From Time To Time Through Jefferies Benzinga

04:57PM EDT Pluristem Therapeutics Inc Files For Mixed Shelf Of Up To $250M Benzinga

Share